Autologous stem cell transplantation (autoHCT) is considered standard of care for newly
diagnosed multiple myeloma (MM). Although most patients eventually progress after …

Background Autologous stem cell transplantation (autoHCT) is the standard of care for
newly-diagnosed MM (NDMM). Although most patients eventually progress, a small …

Autologous stem cell transplantation (ASCT) is an important treatment modality in multiple
myeloma (MM). However, relapse following ASCT is considered almost inevitable. This …

Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with
multiple myeloma (MM) improves survival. However, data to support this approach for …

Background Standard therapy for multiple myeloma (MM) includes initial autologous
hematopoietic cell transplantation (autoHCT1) but this is not curative and most patients will …

Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative
in some, while toxic in many others. We retrospectively analyzed 85 patients diagnosed with …

Introduction Multiple myeloma (MM) is considered an incurable hematological neoplasm.
For transplant-eligible patients, initial treatment includes an induction phase followed by an …

8118 Background: Autologous stem cell transplantation (ASCT) improves survival and
remains the standard of care for patients with newly diagnosed myeloma considered eligible …

Background: Autologous stem cell transplant (ASCT) is the gold standard in the upfront
therapy of younger patients with multiple myeloma (MM). It is considered that ASCT is not …

The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple
myeloma is controversial. We analyzed the results of 205 patients transplanted in one center …